OXFORD, England, November 17, 2016 /PRNewswire/ -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that the first patient in the UK has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the investigational therapy neoGAA. NeoGAA is a second-generation enzyme replacement therapy being studied for the treatment of Pompe disease. The first patient was dosed at the University of Newcastle upon Tyne. "Pompe disease is a serious, progressive and debilitating disorder," said Professor Volker Straub, Principal Investigator at the Newcastle University John Walton Muscular Dystrophy Research Centre and the Newcastle Hospitals NHS Foundation Trust. "Dosingthe first patient in the UKis an exciting and important milestonein our quest to advancetreatment options for patientswith this disease.""Today's news marks a long-awaited step in the continuing effort to developnewtreatments for people living with Pompe disease," added Allan Muir, Charity Director of the Association for Glycogen Storage Disease UK. "The UK patient community is proud to play such an important role in this global trial of a second generation enzyme replacement therapy and we look to forward to following its progress." Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA) affecting an estimated 50,000 people worldwide. Patients often lose their ability to walk and require wheelchairs to assist with mobility. They also often experience difficulty breathing and may require mechanical ventilation to breathe.